drugset / Trial / NCT02387086
Gefitinib Combined With Thalidomide to Treat NSCLC
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether thalidomide can improve the effectiveness of the gefitinib in NSCLC patients with EGFR mutations.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 100 mg | — |
| Background | Aspirin | Small molecule | 100 mg | — |
| Background | Gefitinib | Small molecule | 250 mg | — |